We are delighted to announce the date for the Annual Scientific Meeting which will take place on Thursday 17th November 2022 at the Royal College of Surgeons of Edinburgh. Please join us either in person or virtually for our 34th annual event.
We will be hosting our meeting in the impressive King Khalid Building at the College which was originally St Michael's Church. It boasts a magnificent auditorium with stepped seating and state-of-the-art AV facilities. The King Khalid Building is on Hill Square, directly opposite Ten Hill Place Hotel, where accommodation will be possible alongside your Registration. The downstairs King Khalid Reception Area will house our exhibition, poster display and catering.
Why you should register for this meeting?
Cardiovascular disease, diabetes and all their various clinical manifestations remain one of the most important and frequently seen disease categories in everyday medical practice. Understanding your patients risk of a future cardiovascular event and how we as clinicians can reduce that risk is important to the future well being of our patients.
SHARP Confirmed Keynote Lectures
Professor Roxana Mehran, Professor of Medicine and Director of Interventional Cardiovascular Research and Clinical Trials will be addressing "Reducing the global burden of cardiovascular disease in women: a 20/20 vision for 2030?". Is the risk in women different and do we or should we manage it differently? Find out from Professor Mehran on 17th November.
Professor Sir Rory Collins, Head Of Nuffield Department Of Population Health And BHF Professor Of Medicine And Epidemiology at the University of Oxford will be talking about "Cardiovascular disease prevention: a population-based perspective". Learn from Professor Collins how we should be working to reduce the prevalence of heart attacks and strokes in Scotland.
This year's Scottish Lipid Forum will include a focus on mixed hyperlipidaemia and hypertriglyceridaemia.
SLF Confirmed Speakers
We are delighted to have Professor Anthony Wierzbicki (Guy's & St Thomas', London) joining us to provide an update on approaches to raised triglycerides, and excited to have Professor Deepak Bhatt (Harvard Medical School, Brigham and Women’s Hospital) presenting clinical trial data for Vazkepa.
A full programme will follow shortly.
Prof Roxana Mehran - Reducing the global burden of cardiovascular disease in women
Prof Betty Raman - Are we out of the woods yet? Long term cardiovascular sequelae of COVID-19
Prof Francesco Cappuccio - Management of Cardiovascular Risk in Obstructive Sleep Apnoea
Prof Sir Rory Collins - Cardiovascular disease prevention: a population-based perspective
Christopher Curran - Prevalence of liver fibrosis markers in people with type 2 diabetes
Chloe Hughes - Longitudinal profiling to identify risk of major cardiac events following COVID-19
Dimitrios Doudesis - Machine learning to optimise cardiac troponin diagnosing myocardial infarction
Rebecca Huges - Assessing coronary artery calcification to predict cardiovascular complications
SHARP Prize 2022 winners and closing remarks
This event was funded by the companies mentioned through event sponsorship and sponsored sessions for which we are very grateful.
Alnylam is leading the translation of RNA interference (RNAi) into a whole class of innovative medicines with the potential to help patients who have limited or inadequate treatment options live fuller, healthier lives. Founded in 2002 on the bold vision to turn scientific possibility into reality, Alnylam has a robust discovery platform and deep pipeline of investigational medicines, including several programs in late-stage clinical development. Patients are at the core of everything we do; their needs drive our discoveries and their stories further our commitment to delivering innovative therapies.
Amarin UK Limited
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our scientific research foundation to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly, committed to reducing cardiovascular risk and making a meaningful impact on patients’ lives.
Astra Zeneca UK Limited